Centanafadine for ADHD
Centanafadine is a
- Noradrenaline reuptake inhibitors
- Dopamine reuptake inhibitors
- Serotonin reuptake inhibitors (weak)
Two randomized, double-blind, placebo-controlled, parallel-group phase 3 studies were conducted in adults with ADHD using 200 mg/d or 400 mg/d centanafadine sustained-release tablets.12
At Day 42, both studies showed improvements in AISRS total score compared to placebo with Effect sizes of -0.28 for 200 mg/d and -0.24 for 400 mg/d in Study 1 and -0.37 for 200 mg/d and -0.40 for 400 mg/d in Study 2.
Centanafadine was well tolerated and the overall rate of adverse events was low, but dose-dependent.
Centanafadine is currently being studied in several clinical trials for its efficacy and safety in children and adolescents with ADHD (NCT05279313, NCT05428033, NCT05257265).3
Adler, Adams, Madera-McDonough, Kohegyi, Hobart, Chang D, Angelicola, McQuade, Liebowitz (2022): Efficacy, Safety, and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder: Results of 2 Phase 3, Randomized, Double-blind, Multicenter, Placebo-Controlled Trials. J Clin Psychopharmacol. 2022 Jun 2. doi: 10.1097/JCP.0000000000001575. PMID: 35652746. ↥
Wigal SB, Wigal T, Hobart M, Madera JJ, Baker RA, Kohegyi E, McKinney A, Wilens TE (2020): Safety and Efficacy of Centanafadine Sustained-Release in Adults With Attention-Deficit Hyperactivity Disorder: Results of Phase 2 Studies. Neuropsychiatr Dis Treat. 2020 Jun 8;16:1411-1426. doi: 10.2147/NDT.S242084. PMID: 32606695; PMCID: PMC7292254. ↥
Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schiöth HB (2022): Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022 Nov 17;13:1066988. doi: 10.3389/fphar.2022.1066988. PMID: 36467081; PMCID: PMC9713849. ↥